Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Avipsa Ghosh"'
Autor:
Jeffrey W. Johannes, Fiona Pachl, Amber Balazs, Tieguang Yao, C. Larner, Lisa McWilliams, Marianne Schimpl, Scott W. Martin, Kevin J. Embrey, Tom D. Heightman, Paul Hemsley, Jonathan P. Orme, Derek Barratt, Giuditta Illuzzi, Andrew Madin, Paolo Di Fruscia, Avipsa Ghosh, Martin J. Packer, Scott D. Edmondson, Elisabetta Leo, Xiaolan Zheng, Matthew D. Chuba, Xiaohui Pei, Mark J. O'Connor, Verity Talbot, Ke Zhang, Stephen Fawell, Elizabeth Underwood, Anna Staniszewska, Lina Liu, Lin Xue, Sonja J. Gill, Anders Gunnarsson, Andrew Pike, Susan E. Critchlow, Jeffrey G. Varnes, Andrew X. Zhang, Sébastien L. Degorce, J. Lane, Sudhir M. Hande, Hongyao She, Sabina Cosulich, Michal Bista
Publikováno v:
Journal of Medicinal Chemistry. 64:14498-14512
Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA mutation. However, some have failed in combination with first-line chemotherapies, usually
Publikováno v:
The Journal of organic chemistry. 87(14)
While trifluoromethylthiolation of aryl halides has been extensively explored, the current methods require complex and/or air-sensitive catalysts. Reported here is a method employing a bench-stable Ni(II) salt and an iridium photocatalyst that can me
While the area of trifluoromethylthiolation of aryl halides has been extensively explored, the current methods require complex and/or air-sensitive catalysts. Reported here is a method employing a bench-stable nickel(II) salt and an iridium photocata
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc963fffdd89ad0b587684261d00b8e4
https://doi.org/10.26434/chemrxiv-2021-18xd5
https://doi.org/10.26434/chemrxiv-2021-18xd5
Autor:
Jeffrey W, Johannes, Amber, Balazs, Derek, Barratt, Michal, Bista, Matthew D, Chuba, Sabina, Cosulich, Susan E, Critchlow, Sébastien L, Degorce, Paolo, Di Fruscia, Scott D, Edmondson, Kevin, Embrey, Stephen, Fawell, Avipsa, Ghosh, Sonja J, Gill, Anders, Gunnarsson, Sudhir M, Hande, Tom D, Heightman, Paul, Hemsley, Giuditta, Illuzzi, Jordan, Lane, Carrie, Larner, Elisabetta, Leo, Lina, Liu, Andrew, Madin, Scott, Martin, Lisa, McWilliams, Mark J, O'Connor, Jonathan P, Orme, Fiona, Pachl, Martin J, Packer, Xiaohui, Pei, Andrew, Pike, Marianne, Schimpl, Hongyao, She, Anna D, Staniszewska, Verity, Talbot, Elizabeth, Underwood, Jeffrey G, Varnes, Lin, Xue, Tieguang, Yao, Ke, Zhang, Andrew X, Zhang, Xiaolan, Zheng
Publikováno v:
Journal of medicinal chemistry. 64(19)
Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA mutation. However, some have failed in combination with first-line chemotherapies, usually
Publikováno v:
Angewandte Chemie International Edition. 58:2864-2869
A method for electrophilic sulfenylation by organophosphorus-catalyzed deoxygenative O-atom transfer from sulfonyl chlorides is reported. This C-S bond-forming reaction is catalyzed by a readily available small-ring phosphine (phosphetane) in conjunc
Publikováno v:
Angewandte Chemie. 131:2890-2895
Autor:
Avipsa Ghosh, Sudhir M. Hande, Amber Balazs, Derek Barratt, Sabina Cosulich, Barry Davies, Sébastien Degorce, Kevin Embrey, Sonja Gill, Anders Gunnarsson, Giuditta Illuzzi, Peter Johnström, Jordan Lane, Carrie Larner, Rachel Lawrence, Elisabetta Leo, Andrew Madin, Elizabeth Martin, Lisa McWilliams, Lenka O’Connor, Mark O’Connor, Jonathan Orme, Fiona Pachl, Martin Packer, Andy Pike, Philip Rawlins, Marianne Schimpl, Magnus Schou, Anna Staniszewska, Wenzhan Yang, James Yates, Andrew Zhang, XiaoLa Zheng, Stephen Fawell, Petra Hamerlik, Jeffrey Johannes
Publikováno v:
Cancer Research. 82:6302-6302
PARP inhibitors exploit defects in DNA repair pathways to selectively target cancerous cells via PARP1 catalytic inhibition and PARP1 trapping onto the DNA. All known clinical PARP1 inhibitors bind at the same site at the catalytic center of the enzy
Autor:
Andy Pike, Amber Balazs, Zsolt Cselényi, Sébastien L. Degorce, Avipsa Ghosh, Sudhir M. Hande, Jeffrey Johannes, Peter Johnström, Martin J. Packer, Magnus Schou, XiaoLan Zheng
Publikováno v:
Cancer Research. 82:5076-5076
The current clinically approved PARP inhibitors have limited subtype selectivity and are to some degree restricted in their ability to penetrate the central nervous system (CNS) due to efflux transporters, potentially limiting their efficacy in treat
Autor:
Mark J. O'Connor, Philip B. Rawlins, Kevin J. Embrey, Anders Gunnarsson, Sudhir M. Hande, Anna Staniszewska, Fiona Pachl, Andrew X. Zhang, Jonathan P. Orme, Giuditta Illuzzi, Lisa McWilliams, Sonja J. Gill, Jeffrey W. Johannes, J. Lane, Sébastien L. Degorce, Amber Balazs, Martin J. Packer, Andrew Madin, Marianne Schimpl, Andrew Pike, Elisabetta Leo, Xiaolan Zheng, Avipsa Ghosh, C. Larner
Publikováno v:
Cancer Research. 81:296-296
Since the approval of olaparib in 2014 for BRCA mutated (BRCAm) ovarian cancer, many PARP inhibitors have been developed and have seen widespread success. However, as a class, these drugs are not without adverse events which have limited their abilit